Clinical effects of β-adrenergic blockade in chronic heart failure -: A meta-analysis of double-blind, placebo-controlled, randomized trials

被引:466
作者
Lechat, P
Packer, M
Chalon, S
Cucherat, M
Arab, T
Boissel, JP
机构
[1] Hop La Pitie Salpetriere, Serv Pharmacol, F-75013 Paris, France
[2] Columbia Univ Coll Phys & Surg, Div Circulatory Physiol, New York, NY 10032 USA
[3] Hop Lyon, Unite Pharmacol Clin, Lyon, France
关键词
heart failure; meta-analysis; receptors; adrenergic; beta; trials;
D O I
10.1161/01.CIR.98.12.1184
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background-beta-Blockers have improved symptoms and reduced the risk of cardiovascular events in studies of patients with heart failure, but it is unclear which end points are most sensitive to the therapeutic effects of these drugs. Methods and Results-We combined the results of all 18 published double-blind, placebo-controlled, parallel-group trials of beta-blockers in heart failure. From this combined database of 3023 patients, we evaluated the strength of evidence supporting an effect of treatment on left ventricular ejection fraction, NYHA functional class, hospitalizations for heart failure, and death, beta-Blockers exerted their most persuasive effects on ejection fraction and on the combined risk of death and hospitalization for heart failure. beta-Blockade increased the ejection fraction by 29% (P<10(-9)) and reduced the combined risk of death or hospitalization for heart failure by 37% (P<0.001). Both effects remained significant even if >90% of the trials were eliminated from the analysis or if a large number of trials with a neutral result were added to the analysis. In contrast, the effect of beta-blockade on NYHA functional class was of borderline significance (P=0.04) and disappeared with the addition or removal of only 1 moderate-size study. Although beta-blockade reduced all-cause mortality by 32% (P=0.003), this effect was only moderately robust and varied according to the type of beta-blocker tested, ie, the reduction of mortality risk was greater for nonselective beta-blockers than for beta(1)-selective agents (49% versus 18%, P=0.049). However, selective and nonselective beta-blockers did not differ in their effects on other measures of clinical efficacy. Conclusions-These analyses indicate that there is persuasive evidence supporting a favorable effect of beta-blockade on ejection fraction and the combined risk of death and hospitalization for heart failure. In contrast, the effect of these drugs on other end points requires additional study.
引用
收藏
页码:1184 / 1191
页数:8
相关论文
共 39 条
  • [1] Baptista J., 1977, Applied Statistics, V26, P214, DOI 10.2307/2347041
  • [2] beta(2)-Adrenergic receptor antagonists protect against ventricular fibrillation - In vivo and in vitro evidence for enhanced sensitivity to beta(2)-adrenergic stimulation in animals susceptible to sudden death
    Billman, GE
    Castillo, LC
    Hensley, J
    Hohl, CM
    Altschuld, RA
    [J]. CIRCULATION, 1997, 96 (06) : 1914 - 1922
  • [3] CONSIDERATIONS FOR THE METAANALYSIS OF RANDOMIZED CLINICAL-TRIALS - SUMMARY OF A PANEL DISCUSSION
    BOISSEL, JP
    BLANCHARD, J
    PANAK, E
    PEYRIEUX, JC
    SACKS, H
    [J]. CONTROLLED CLINICAL TRIALS, 1989, 10 (03): : 254 - 281
  • [4] Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure
    Bristow, MR
    Gilbert, EM
    Abraham, WT
    Adams, KF
    Fowler, MB
    Hershberger, RE
    Kubo, SH
    Narahara, KA
    Ingersoll, H
    Krueger, S
    Young, S
    Shusterman, N
    [J]. CIRCULATION, 1996, 94 (11) : 2807 - 2816
  • [5] DOSE-RESPONSE OF CHRONIC BETA-BLOCKER TREATMENT IN HEART-FAILURE FROM EITHER IDIOPATHIC DILATED OR ISCHEMIC CARDIOMYOPATHY
    BRISTOW, MR
    OCONNELL, JB
    GILBERT, EM
    FRENCH, WJ
    LEATHERMAN, G
    KANTROWITZ, NE
    ORIE, J
    SMUCKER, ML
    MARSHALL, G
    KELLY, P
    DEITCHMAN, D
    ANDERSON, JL
    [J]. CIRCULATION, 1994, 89 (04) : 1632 - 1642
  • [6] BETA-1-ADRENERGIC-RECEPTOR AND BETA-2-ADRENERGIC-RECEPTOR SUBPOPULATIONS IN NONFAILING AND FAILING HUMAN VENTRICULAR MYOCARDIUM - COUPLING OF BOTH RECEPTOR SUBTYPES TO MUSCLE-CONTRACTION AND SELECTIVE BETA-1-RECEPTOR DOWN-REGULATION IN HEART-FAILURE-
    BRISTOW, MR
    GINSBURG, R
    UMANS, V
    FOWLER, M
    MINOBE, W
    RASMUSSEN, R
    ZERA, P
    MENLOVE, R
    SHAH, P
    JAMIESON, S
    STINSON, EB
    [J]. CIRCULATION RESEARCH, 1986, 59 (03) : 297 - 309
  • [7] THE COMBINATION OF ESTIMATES FROM DIFFERENT EXPERIMENTS
    COCHRAN, WG
    [J]. BIOMETRICS, 1954, 10 (01) : 101 - 129
  • [8] Cohn J N, 1997, J Card Fail, V3, P173, DOI 10.1016/S1071-9164(97)90013-0
  • [9] Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure
    Colucci, WS
    Packer, M
    Bristow, MR
    Gilbert, EM
    Cohn, JN
    Fowler, MB
    Krueger, SK
    Hershberger, R
    Uretsky, BF
    Bowers, JA
    SacknerBernstein, JD
    Young, ST
    Holcslaw, TL
    Lukas, MA
    [J]. CIRCULATION, 1996, 94 (11) : 2800 - 2806
  • [10] Meta-analysis: A method for synthesizing research
    DAgostino, RB
    Weintraub, M
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 58 (06) : 605 - 616